Patents by Inventor Lixin Qiao

Lixin Qiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kit and method for constructing long-acting depression animal model
    Patent number: 11963519
    Abstract: The present disclosure provides a kit and method for constructing a long-acting depression animal model. The present disclosure adopts Bacille Calmette-Guerin (BCG) (or Mycobacterium bovis (M bovis)) and low-dose pertussis toxin (PTX) for combined induction, which greatly reduces modeling cost. A mouse model constructed by the method of the present disclosure can clearly distinguish a time interval of pathological behaviors from a time interval of depression-like behaviors and has prominent face validity and predictive validity. The method of the present disclosure is simple and convenient and does not require a large number of tedious daily operations as the depression model construction by chronic unpredictable stress, chronic restraint stress, social defeat, mother-child separation, or the like. The mouse model of the present disclosure can provide a valuable long-term intervention window for research on antidepressant therapy.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: April 23, 2024
    Assignee: Northwest Institute of Plateau Biology, CAS
    Inventors: Cen Li, Hongxia Yang, Jing Zhao, Lixin Wei, Yuzhi Du, Yuancan Xiao, Hongtao Bi, Zhanjuan Chen, Yajun Qiao, Jianv Wang
  • Ligand-directed covalent modification of protein
    Patent number: 11542492
    Abstract: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: January 3, 2023
    Assignee: Celgene CAR LLC
    Inventors: Russell C. Petter, Charles F. Jewell, Kwangho Lee, Aravind Prasad Medikonda, Deqiang Niu, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 11351168
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: June 7, 2022
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Compounds that enhance Atoh1 expression
    Patent number: 11160808
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 2, 2021
    Assignees: Massachusetts Eye & Ear Infirmary, Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • MK2 inhibitors and uses thereof
    Patent number: 11098061
    Abstract: The present invention provides compounds of formula V: or pharmaceutically acceptable salts thereof, useful as inhibitors of MK2 kinases, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Patent number: 10828300
    Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 10, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Compounds that Enhance Atoh1 Expression
    Publication number: 20200179394
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Application
    Filed: July 22, 2019
    Publication date: June 11, 2020
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Protein kinase conjugates and inhibitors
    Patent number: 10662195
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: May 26, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 10596172
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 24, 2020
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Compounds that enhance Atoh1 expression
    Patent number: 10406163
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: September 10, 2019
    Assignees: Massachusetts Eye & Ear Infirmary, The Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190192512
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 29, 2018
    Publication date: June 27, 2019
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • MK2 INHIBITORS AND USES THEREOF
    Publication number: 20190135835
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 9, 2019
    Inventors: Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190117650
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 25, 2019
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • MK2 inhibitors and uses thereof
    Patent number: 10138256
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 27, 2018
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 10010548
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: July 3, 2018
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Patent number: 9987276
    Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 5, 2018
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • ERK inhibitors and uses thereof
    Patent number: 9980964
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 29, 2018
    Assignee: CELGENE CAR LLC
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • ERK inhibitors and uses thereof
    Patent number: 9796700
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: October 24, 2017
    Assignee: Celgene CAR LLC
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • Ligand-Directed Covalent Modification of Protein
    Publication number: 20170218353
    Abstract: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Inventors: Russell C. Petter, Charles F. Jewell, Kwangho Lee, Aravind Prasad Medikonda, Deqiang Niu, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • ERK INHIBITORS AND USES THEREOF
    Publication number: 20170210729
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 2, 2017
    Publication date: July 27, 2017
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu